Atkinson Edward Morrow III's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Feb 19, 2026
- Accession no.
- 0000875320-26-000082
- Filed
- Feb 19, 2026
- Trade date
- Feb 17-18, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.38M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Atkinson Edward Morrow IIICIK 0001914164 | Officer (EVP, Chief Technical Ops. Off.) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | Common Stock | AGrant or awardAcquired | +4,962 | $0.00 | $0 | 25,105 | Direct | |
| Feb 17, 2026 | Common Stock | FTax withholdingDisposed | −1,530 | $483.75 | −$740,137.5 | 23,575 | Direct | |
| Feb 17, 2026 | Common Stock | SSaleDisposed | −2,031 | $489.46 | −$994,093.26 | 21,544 | Direct | |
| Feb 18, 2026 | Common Stock | SSaleDisposed | −817 | $473.68 | −$386,996.56 | 20,727 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.